What stage does Aescap Life Sciences invest at?

Aescap Life Sciences invests at the Seed, Series A, Growth stages.

What sectors does Aescap Life Sciences focus on?

Aescap Life Sciences focuses on AI & Machine Learning, Biotech, Healthtech, Longevity, Medical Devices.

Where is Aescap Life Sciences located?

Aescap Life Sciences is headquartered in Amsterdam, NL.

Aescap Life Sciences

Crossover fund

Amsterdam · Seed–Growth · 14 people tracked

★ Follow + Add to CRM ⤳ Find an introduction

✨ Fox Verdict

Investment thesis

Aescap runs high-conviction portfolios of about 20 carefully selected publicly listed biotech companies, chosen from roughly 900 candidates based on management quality, distinctive medicines, and attractive valuation. The firm focuses on companies leading the application of AI in research and development, which shortens timelines, cuts costs, and improves clinical success. It targets growth sectors with high unmet medical need driven by aging populations and rising demand for effective therapies. The team combines deep scientific expertise (professionals with over thirty years of sector experience) with disciplined investment and divestment processes, seeking diversified exposure across technologies, disease areas, development stages, and regions.

Invests inAI & Machine Learning Biotech Healthtech Longevity Medical Devices Amsterdam Austria Belgium Denmark Finland France Germany Global Netherlands Norway Sweden Switzerland

Source: firm website, verified Aug 3, 2026.

Stage

Seed–Growth

Amsterdam, NL

Instruments

Equity

Founded

2005

Team · 14 people

from the firm's website & public directories

Patrick Krol· Founder & Portfolio Manager· Amsterdam, North Holland, Netherlandsin

Founder and Portfolio Manager who joined Aescap at its 2005 founding and became managing/general partner in 2009, leading the firm's shift to public-market biotech investing. Has served as non-executive director at numerous biotech and diagnostics companies and previously led a European biotech consultancy.

p•••@aescap.comreveal

Paolo del Bufalo· Investment Manager

Joined Aescap as an analyst in 2018 and became an investment manager in 2023. Holds a chemistry degree from La Sapienza and master's tracks at Leiden University in chemical biology and science-based business.

p•••@aescap.comreveal

Bo Jesper Hansen· Portfolio Advisor

Portfolio Advisor, M.D., Ph.D., former Executive Chairman of SOBI AB and chairman of several biotech firms, with extensive expertise in clinical trial design, regulatory affairs, and business development.

Gert Hoogland· Portfolio Advisor

Portfolio Advisor, M.D., MBA, a pharmaceutical executive who held CEO roles at Schering AG, founded a leading African specialty pharma distributor, and later ran a healthcare investment and consulting company in Zurich.

Lincoln Lukose· AI & data science specialist· Leidschendam, South Holland, Netherlandsin

AI and data science specialist building AI-powered tools for due diligence, valuation, investor-momentum tracking, and ESG reporting. Holds a master's in bioinformatics and systems biology and studied AI in healthcare at MIT.

Ludovico Dragoni· Analyst· Amsterdam, North Holland, Netherlandsin

Analyst with degrees in biotechnology and medical biotechnology from La Sapienza and an advanced master's from Solvay. Previously worked in pharma consulting, co-founded a biotech startup, and analyzed biotech deals at Newton Biocapital.

Maarten Hendriks· Portfolio Advisor

Portfolio Advisor with over twenty years at Boehringer Ingelheim in medical and regional management roles across Europe, China, and emerging markets. Holds a pharmacy degree and a PhD in cardiovascular pharmacology.

Peter Hintzen· Portfolio Advisor

Portfolio Advisor trained as a surgeon specializing in gastrointestinal and thoracic surgery, with experience establishing private clinics and working as a surgeon in France and the Netherlands.

Sam Frenay· Quantitative Analyst· London, England, United Kingdomin

Quantitative Analyst who develops proprietary investment strategies combining medical, finance, and AI backgrounds. Holds a BSc in Medicine from Leiden, a master's from Cornell in machine learning for finance, and a CEMS master's from LSE.

Victor Bakker· Head of Investor Relations· Amsterdam, North Holland, Netherlandsin

Head of Investor Relations responsible for reporting and onboarding new investors. Holds a Master's in Entrepreneurship in Life Sciences and previously worked at a boutique consultancy specializing in strategic financing for life-sciences companies.

s•••@aescap.comreveal

Alba Montoro· Analyst· Barcelona, Catalonia, Spainin

a•••@aescap.comreveal

Jonas van Dam· Analyst

j•••@aescap.comreveal

Pien Kiliaan· Senior Analyst

Senior Analyst who studied pharmaceutical sciences at Utrecht University and completed a master's in business and research at Leiden University, with research experience at the Leiden Academic Centre for Drug Research and Harvard Medical School.

p•••@aescap.comreveal

Suzette Pinto· Analyst

s•••@aescap.comreveal

Frequently asked questions

What stage does Aescap Life Sciences invest at?: Aescap Life Sciences invests at the Seed, Series A, Growth stages.
What sectors does Aescap Life Sciences focus on?: Aescap Life Sciences focuses on AI & Machine Learning, Biotech, Healthtech, Longevity, Medical Devices.
Where is Aescap Life Sciences located?: Aescap Life Sciences is headquartered in Amsterdam, NL.

Similar investors

GV (Google Ventures)

GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.

$250K – $50M

Khosla Ventures

Khosla Ventures is a venture capital firm founded by Vinod Khosla.

$5K – $50M

Averin Capital

Averin Capital is an investment firm focused on the intersection of technology and health, backing teams building companies in areas such as early disease detection, treatment delivery, personalized care, and medical breakthroughs.

JAZZ Venture Partners

JAZZ Venture Partners is a venture capital firm investing in companies at the intersection of technology, neuroscience, and human performance, spanning digital health, biosciences, and AI.

$100K – $20M

Foresite Capital

Foresite Capital is a healthcare-focused investment firm backing companies at the intersection of technology and biotechnology to personalize healthcare and accelerate medical innovation.